FDA
-
-
-
-
-
-
-
Morgan Stanley on iRhythm Technologies (IRTC): 'Solid pre-announce'
-
-
-
-
-
-
-
AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies’ Zio LTCM Service
-
-
-
-
-
-
-
iRhythm Technologies (IRTC) PT Raised to $145 at Truist Following EBITDA/EPS Beat
-
-
-
-
-
-
-
iRhythm Technologies (IRTC) Receives FDA 510(k) Clearance for Design Modifications to Its Zio AT Device
-
-
-
-
-
-
-
iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device
-
-
-
-
-
-
-
iRhythm Technologies Announces Second Quarter 2024 Financial Results
-
-
-
-
-
-
-
INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that iRhythm Technologies, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - IRTC
-
328,148 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

